BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 17634876)

  • 1. [Chemotherapeutics-induced heart failure].
    Paulides M; Wojnowski L
    Med Klin (Munich); 2007 Jul; 102(7):574-8. PubMed ID: 17634876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exposure to anthracyclines during childhood causes cardiac injury.
    Lipshultz SE
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies.
    Wouters KA; Kremer LC; Miller TL; Herman EH; Lipshultz SE
    Br J Haematol; 2005 Dec; 131(5):561-78. PubMed ID: 16351632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anthracycline-induced cardiomyopathy.
    Simmons A; Vacek JL; Meyers D
    Postgrad Med; 2008 Nov; 120(4):67-72. PubMed ID: 19020367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies for reduction of anthracycline cardiac toxicity.
    Speyer J; Wasserheit C
    Semin Oncol; 1998 Oct; 25(5):525-37. PubMed ID: 9783592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines.
    Pouillart P
    Cancer Treat Rev; 2004 Nov; 30(7):643-50. PubMed ID: 15531396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathophysiology and diagnosis of cancer drug induced cardiomyopathy.
    Zuppinger C; Timolati F; Suter TM
    Cardiovasc Toxicol; 2007; 7(2):61-6. PubMed ID: 17652805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer.
    Jensen BV
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S15-21. PubMed ID: 16781285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacologic prevention of anthracycline-induced cardiomyopathy.
    Maradia K; Guglin M
    Cardiol Rev; 2009; 17(5):243-52. PubMed ID: 19690476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotyping the risk of anthracycline-induced cardiotoxicity.
    Deng S; Wojnowski L
    Cardiovasc Toxicol; 2007; 7(2):129-34. PubMed ID: 17652817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Severe heart failure in consequence of late anthracycline-induced cardiotoxicity--case report].
    Urbanová D; Bubanská E; Hrebík M; Mladosievicová B
    Klin Onkol; 2009; 22(1):34-7. PubMed ID: 19534438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenesis of cardiotoxicity induced by anthracyclines.
    Elliott P
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S2-7. PubMed ID: 16781283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cardiotoxicity of anthracyclines].
    Costache II; Petriş A
    Rev Med Chir Soc Med Nat Iasi; 2011; 115(4):1200-7. PubMed ID: 22276470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
    Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; Calabrò R
    Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity.
    Herman EH; Ferrans VJ
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):15-21. PubMed ID: 9768819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dexrazoxane as a cardioprotectant in children receiving anthracyclines.
    Sepe DM; Ginsberg JP; Balis FM
    Oncologist; 2010; 15(11):1220-6. PubMed ID: 21051660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiotoxicity of cytotoxic drugs.
    Schimmel KJ; Richel DJ; van den Brink RB; Guchelaar HJ
    Cancer Treat Rev; 2004 Apr; 30(2):181-91. PubMed ID: 15023436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac complications in childhood cancer survivors treated with anthracyclines.
    Franco VI; Lipshultz SE
    Cardiol Young; 2015 Aug; 25 Suppl 2():107-16. PubMed ID: 26377717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Control of the myocardial pump function during cytostatic treatment with anthracycline].
    Hesse B; Mouridsen HT; Schaadt BK; Meyer C
    Ugeskr Laeger; 1996 Aug; 158(33):4628-30. PubMed ID: 8760518
    [No Abstract]   [Full Text] [Related]  

  • 20. Cardiac toxicity after anthracycline chemotherapy in childhood.
    Iarussi D; Indolfi P; Galderisi M; Bossone E
    Herz; 2000 Nov; 25(7):676-88. PubMed ID: 11141677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.